Home
About EEP
Investment Orientation
Portfolio
The Team
News


 

 

 

Investor Reporting
Contact Us
Site Map
Terms & Conditions



EEP News

22/01/2018
AGC Biologics to Hold Technical Seminar in Taiwan

08/01/2018
AGC Bioscience, Biomeva, and CMC Biologics to provide services under the brand AGC Biologics

18/12/2017
Azanta: Angusta® is now approved in 16 EU countries

12/12/2017
CMC Biologics Announces Development and Manufacturing Agreement with Harpoon Therapeutics

22/08/2017
CMC Biologics and Aptevo Therapeutics Enter into Commercial Manufacturing Agreement for IXINITY®

27/07/2017
CMC Biologics Enters into Development and Manufacturing Agreement with Trellis BioScience

13/04/2017
Altor BioScience and CMC Biologics Announce Agreement for Manufacture and Validation of Altor's IL-15 Superagonist Molecule, ALT-803, for use in Phase 3 Clinical Trials

14/03/2017
Appointment of new Azanta CEO and market launch of Angusta

25/02/2017
Azanta A/S files Marketing Authorisation Application for Angusta®

16/02/2017
CMC Biologics and Genexine, Inc. Announce Manufacturing Agreement for Genexine's Human Growth Hormone Drug, GX-H9

15/02/2017
CMC Biologics Enters into Manufacturing Agreement with CytoDyn

19/12/2016
AGC Asahi Glass Signs Agreement to Acquire CMC Biologics

14/12/2016
Azanta A/S Welcomes Bo Jesper Hansen as Board Member

02/11/2016
CMC Biologics Participates in Denmark State Visit to Korea

11/10/2016
CMC Biologics and IDT Biologika Announce the Addition of Cerbios-Pharma and Oncotec Pharma to their Strategic Collaboration

15/06/2016
CMC Biologics Cleared for Commercial Manufacture of CSL Behring's FDA-Approved AFSTYLA

02/06/2016
CMC Biologics Expands GMP Manufacturing Capacity in Europe

29/05/2016
Catslyst Biosciences and CMC Biologics Announce Manufacturing Agreement for Catalyst's Next-Generation Factor VIIa Product CB 813d

29/03/2016
CMC Biologics Recognized as a Leader in Contract Development and Manufacturing by Customers and the Biopharmaceutical Industry.

25/02/2016
Azanta A/S files Marketing Authorisation Application for Angusta®

17/02/2016
CMC Biologics and IDT Biologika Announce a Strategic Collaboration to Manufacture Antibody Drug Conjugates

14/12/2015
Azanta A/S welcomes Bo Jesper Hansen as a member of the Board of Directors and David Kauffmann as the vice-chairman of the Board

02/10/2015
Azanta A/S Completes DKK 46.4 million Capital Increase

12/08/2015
CMC Biologics Enters into Agreement with the PATH Malaria Vaccine Initiative for Accelerated Development and Manufacturing of Monoclonal Antibodies

29/07/2015
CMC Biologics and River Vision Development Corporation Announce Manufacturing Agreement for RV001, a Monoclonal Antibody to Treat Grave's Orbitopathy

30/06/2015
CMC Biologics Expands GMP Manufacturing Capacity in the United States

20/05/2015
CMC Biologics Expands European GMP Manufacturing Capacity

07/05/2015
CMC Biologics Expands GMP Manufacturing Capacity in the United States and Europe

05/05/2015
CMC Biologics in Commercial Supply Agreement with Emergent BioSolutions for FDA-Approved IXINITY®

19/03/2015
CMC Biologics Recognized for Quality and Reliability at the 2015 CMO Leadership Awards Ceremony

30/01/2015
Serendex Pharmaceuticals and CMC Biologics Enter Exclusive Agreement on Factor VIIa

16/12/2014
CMC Biologics and OncoSynergy Enter into an Agreement for Accelerated Process Development and GMP Manufacture of an Investigational Drug to Combat Ebola

03/12/2014
Joseph Wypych, 20-year Biopharmaceutical Executive, Joins CMC Biologics as General Manager, Seattle Facility

03/09/2014
CMC Biologics and Zymeworks Enter into Agreement for Process Development and Clinical Manufacture of Bi-Specific Antibody Product Candidate

02/07/2014
CMC Biologics Enters into Commercial Supply Agreement with Portola Pharmaceuticals for Manufacturing of First-In-Class Factor Xa Inhibitor Antidote Andexanet Alfa

17/06/2014
CMC Biologics and MacroGenics Enter into Process Validation and Clinical Manufacturing Agreement for Commercialization of Next-Generation Oncology Product Candidate

06/05/2014
CMC Biologics and MacroGenics Enter into a Process Development and Manufacturing Agreement for Oncology Product Candidate

02/04/2014
CMC Biologics Wins 2014 CMO Leadership Awards for Innovation, Quality and Reliability

08/01/2014
Jesper Bramming Joins the CMC Biologics Executive Management Team as Chief Financial Officer

17/12/2013
CMC Biologics and OncoSynergy Enter into Agreement to Develop and Manufacture Material for IND Enabling Studies and Phase I Clinical Trials

03/12/2013
CMC Biologics Enters into Agreement with the University of Copenhagen for Development and Clinical Manufacture of Placental Malaria Vaccine

15/10/2013
CMC Biologics Achieves Authorization for cGMP Commercial Manufacturing by the Danish Medicines Agency

14/05/2013
CMC Biologics and RuiYi Enter into an Agreement for Development of a Novel Anti-IL-6 Monoclonal Antibody

19/03/2013
CMC BiologicsWins 2013 CMO Leadership Award for Innovation, Quality and Reliability

12/09/2012
CMC Biologics Establishes Commercial Presence In Japan through Strategic Agreement with Innomedica

10/09/2012
CMC Biologics Announces Mark W. Sawicki as Global Vice President, Business Development

30/08/2012
CMC Biologics Announces New General Manager of Copenhagen Facility

31/07/2012
CMC Biologics to Buy XOMA's Manufacturing Facility - San Francisco Business Times

31/07/2012
CMC Biologics Acquires XOMA's Bay Area Manufacturing Facility - Fierce Biotech

31/07/2012
CMC Biologics Buys Bay Area Manufacturing Facility - Northwest Innovation

31/07/2012
CMC Biologics Snaps Up Biotech Manufacturing Plant from XOMA -- Xconomy

31/07/2012
CMC Biologics Acquires XOMA's Bay Area Manufacturing Facility - Bezinga

31/07/2012
CMC Biologics in BioSpace News

31/07/2012
CMC Biologics Acquires XOMA's Bay Area Manufacturing Facility

18/07/2012
Contract Pharma: "A Chat with CMC Biologics at BIO 2012" by Mak Jawadekar

18/06/2012
CMC Achieves Pre-Approval by MHRA for Commercial Manufacturing

02/05/2012
CMC Honored as Finalist for Washington's Manufacturing Company of the Year Award

16/04/201
CMC Biologics Highlights Technical Acumen at Numerous Conferences

05/01/2012
CMC Strengthens its Biomanufacturing Technology Portfolio


EEP Advisers Limited is Authorised and Regulated by the Financial Conduct Authority